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During myocardial ischemia, the tissue levels of long chain acylcarnitines, such as palmitoyl-L-carnitine, in crease markedly because of inhibition of mitochondrial p-oxidation of free fatty acids (1, 2) . Long-chain acyl carnitines that have accumulated in the tissue are prefer entially incorporated into phospholipid bilayers of the sarcolemmal membrane and cause a disturbance in the homeostasis of ions in the cardiac cells (1, 2) . Therefore, long-chain acylcarnitines are considered to be one of the factors involved in production of irreversible damage in the ischemic heart (1-4). In fact, palmitoyl-L-carnitine produces severe mechanical dysfunction (5), electro physiological alterations (4, 6, 7) and membrane dys function (8) in the heart. This view can be supported by the fact that inhibitors of carnitine acyltransferase I attenuate both tissue accumulation of long-chain acyl carnitines and myocardial ischemic derangements in situ (3) and in vitro (4, 9) .
Recently we found that dilazep, a coronary dilator producing a cardioprotective effect, attenuates mechani cal dysfunction induced by exogenous palmitoyl-L-carni tine in the isolated rat heart (10). The action of dilazep to attenuate the palmitoyl-L-carnitine-induced derangements may contribute to its cardioprotective action against ischemia-reperfusion damage. One of the characteristic pharmacological properties of dilazep is reported to be potentiation of the cardiovascular effects of adenosine through inhibition of adenosine uptake into cardiac and endothelial cells (5, 11, 12) . The beneficial action of dilazep on the palmitoyl-L-carnitine-induced mechanical dysfunction, however, is not due to potentiation of the cardiovascular effects of adenosine but due to unknown actions (10) . Interestingly, dilazep has a potent blocking action on the Na+ channel in cardiac cells (13, 14) , and palmitoyl-L-carnitine causes opening of Na+ channels in cardiomyocytes (6, 7) . These facts lead to a view that the beneficial effect of dilazep on the palmitoyl-L-carnitine induced mechanical dysfunction may be due to inhibition of the cardiac Na+ channel, although it is unclear whether inhibition of the Na+ channel is important in attenuating the palmitoyl-L-carnitine-induced mechanical dysfunction. In the present study, therefore, the effect of tetrodotoxin, a specific inhibitor of the Na+ channel, on mechanical dysfunction induced by palmitoyl-L-carnitine was studied in the isolated rat heart, and compared with that of dilazep. We also examined the effects of dilazep and tetrodotoxin on the palmitoyl-L-carnitine-induced changes in energy metabolism in the heart because palmitoyl-L-carnitine has a harmful effect on the energy metabolism (15) .
MATERIALS AND METHODS

Heart perfusion
The protocol of animal experiments in the present study was approved by the "Asahikawa Medical College Committee on Animal Research". Male Sprague-Dawley rats (9 to 10-weeks-old; Sankyo Labo Service Corpora tion, Sapporo) were used in the present study. They were supplied with food and water ad libitum and injected with heparin (1,000 units/kg, i.p.) 30 min before induction of anesthesia. Under anesthesia with sodium pentobarbital (50 mg/kg, i.p.), the thorax was opened and the hearts were rapidly removed. Retrograde perfusion was started using a cannula inserted into the aorta according to the Langendorff technique. The perfusion buffer was a Krebs-Henseleit bicarbonate (KHB) buffer containing 118 mM NaCI, 4.7 mM KCI, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaC12, 25 mM NaHCO3 and 11 mM glu cose, equilibrated with a gas mixture of 95% 02 + 5 % CO2 and maintained at 371C. The oxygen tension of the buffer measured by a blood gas analyzer (Model 813; Instrumentation Laboratory, Lexington, MA, USA) was about 550 mmHg. The hearts were initially perfused at a constant perfusion pressure of 80 cmH2O. About 10 min after constant pressure perfusion, perfusion was switched to a constant flow perfusion (10 ml/min) using a microtube pump (Eyela MP-3; Tokyo-Rikakikai Instruments, Tokyo), and this flow rate was maintained constant throughout the experiment. The heart rate was kept constant by pacing the heart at 300 beats/min with an electronic stimulator (3F46; San-Ei Instruments, Tokyo) during the course of the study. Rectangular pulses having 2-msec duration with the voltage of 6 V (about 3 times the threshold voltage) were applied to the left ventricle for pacing of the heart.
As indices of mechanical function, left ventricular sys tolic pressure (LVSP), left ventricular end-diastolic pres sure (LVEDP) and left ventricular developed pressure (LVDP) were employed. The values of LVSP and LVEDP were determined from the left ventricular pres sure (LVP) curves recorded continuously during the course of the study, and the LVDP value was calculated as LVSP minus LVEDP. For measurement of LVP, a saline-filled polyethylene cannula, connected to a pressure transducer, was inserted into the left ventricular cavity via the left atrium. Before starting the experiments, the heart was allowed to stabilize for 20 min under the conditions of constant flow perfusion.
Experimental protocol
The effect of dilazep or tetrodotoxin on the mechanical function and energy metabolism was examined in both palmitoyl-L-carnitine-treated heart and normal heart experiments. In the normal heart experiments, the heart was not treated with palmitoyl-L-carnitine.
Dilazep, tetrodotoxin or vehicle (KHB buffer for both dilazep and tetrodotoxin) was infused into the aortic cannula for 45 min at a constant flow rate of 0.1 ml/min. In the palmitoyl-L-carnitine-treated heart experiments, pal mitoyl-L-carnitine was infused into the aortic cannula at the constant flow rate of 0.1 ml/min for 10 min from 10 min after starting the infusion of dilazep, tetrodotoxin or vehicle. The experimental conditions and protocol of the normal heart experiments were essentially the same as in the palmitoyl-L-carnitine-treated heart experiments, ex cept for an infusion of KHB buffer solution instead of palmitoyl-L-carnitine solution. In each group, LVSP, LVEDP and LVDP were continuously recorded before and during the infusion of dilazep, tetrodotoxin or vehi cle. To measure the tissue levels of high-energy phos phates, the heart was frozen at the end of the observation period (45 min after the start of infusion of dilazep, tetrodotoxin or vehicle) with freezing clamps previously chilled in liquid nitrogen.
Biochemical analysis
The frozen myocardial samples were stored in liquid nitrogen (at 173 °C) until the biochemical analysis was performed. The frozen myocardial sample was pulverized in a mortar cooled with liquid nitrogen. To measure the tissue water content and dry weight of the tissue, a part of the pulverized tissue powder was weighed and put into an oven and allowed to stand in it overnight. The remainder of the tissue powder was used for determination of the tissue levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and creatine phosphate (CrP). ATP, ADP, AMP and CrP were extracted from the pulverized tissue sample with 6° perchloric acid. The tissue extract was centrifuged at 10,000 x g for 10 min at 4'C. The supernatant was neutralized by 70% KOH and centrifuged at 10,000 x g for 10 min at 4°C again. The resultant solution was used for determination of ATP, ADP, AMP and CrP. These metabolites were measured according to the standard enzymatic procedures (16) using a spectrophotometer (Gilford system 2600; Gilford Instrument Laboratories Inc., Oberlin, OH, USA).
Drugs
Dilazep dihydrochloride (Kowa Pharmaceutical Co., Ltd., Tokyo), tetrodotoxin (Sankyo Co., Ltd., Tokyo) and palmitoyl-L-carnitine (Sigma Chemical Company, St. Louis, MO, USA) were dissolved in KHB buffer solution. Dilazep, tetrodotoxin or vehicle (KHB buffer solution) was infused at a flow rate of 0.1 ml/min, by an infusion pump, into the inflow tube connected to the side arm of the aortic cannula. Palmitoyl-L-carnitine or KHB buffer solution was also infused to the inflow tube at a flow rate of 0.1 ml/min with another infusion pump. The final concentration of dilazep in the perfusate (KHB buffer perfused at a flow rate of 10 ml/min plus dilazep solution infused at a flow rate of 0.1 ml/min) was set to 0.1 or 1 aM. Nevertheless, the concentration of dilazep changed from 0.1 to 0.099 pM or 1 to 0.99 pM when palmitoyl-L carnitine was added to the perfusate because the total flow rate of perfusate increased from 10.1 ml/min to 10.2 ml/min during the palmitoyl-L-carnitine infusion. Tetrodotoxin was also infused into the aortic cannula at a flow rate of 0.1 ml/min so that the final concentration of tetrodotoxin in the perfusate was 1 or 3 pM, although the concentration of tetrodotoxin changed from 1 to 0.99 pM or 3 to 2.97 pM during the infusion of palmitoyl-L-carni tine. These small changes in the concentration of dilazep or tetrodotoxin were about 1% and did not affect LVP. The final concentration of palmitoyl-L-carnitine in the perfusate including infusion solution was 5 pM. The re agents and enzymes used for biochemical analysis were purchased from Sigma Chemical Company.
Statistical analyses
All values are expressed as means±S.E.M. When mechanical data were compared between vehicle-treated and drug-treated groups, statistical analysis was per formed with a two-way repeated measures ANOVA fol lowed by Dunnett's test for multiple comparison. When the metabolic data were compared between vehicle and palmitoyl-L-carnitine + vehicle groups, the unpaired Student's t-test was employed. When metabolic data were compared between vehicle-treated and drug-treated groups, statistical analysis was performed with a one-way ANOVA followed by Dunnett's test for multiple com parison. A difference was considered statistically sig nificant at P < 0.05 . 
RESULTS
Mechanical function
In the normal heart, dilazep (0.1 and 1 pM) or tetrodotoxin (1 and 3 pM) did not have any effect on the LVSP (P>0.05 by ANOVA for each concentration of dilazep or tetrodotoxin) and LVEDP (P>0.05 by ANOVA for each concentration of dilazep or tetrodo toxin) during the entire course of the study (data not shown). Figures 1 and 2 show the effects of dilazep and tetrodotoxin, respectively, on the palmitoyl-L-carnitine induced changes in LVSP and LVEDP. In the palmitoyl L-carnitine-treated heart, there was no significant differ ence in the values of LVSP and LVEDP before starting the palmitoyl-L-carnitine infusion (0, 5 and 10 min in Figs. 1 and 2 ) between the palmitoyl-L-carnitine + vehicle and palmitoyl-L-carnitine + dilazep groups and between the palmitoyl-L-carnitine + vehicle and palmitoyl-L-carni tine + tetrodotoxin groups. In the palmitoyl-L-carnitine + vehicle group, palmitoyl-L-carnitine produced a long lasting decrease in LVSP (P<0.001 by ANOVA) follow These results indicate that both dilazep and tetrodotoxin attenuate the metabolic derangements induced by palmitoyl-L-carnitine.
DISCUSSION
In the present study, the effect of dilazep or tetrodo toxin on the palmitoyl-L-carnitine-induced mechanical and metabolic derangements was examined in the isolated perfused rat heart. The concentration of palmitOyl-L carnitine was chosen as 5 pM for the following three rea sons: First, this is the submaximal concentration that produces a long-lasting mechanical dysfunction (10) . Second, administration of 5 pM palmitoyl-L-carnitine may inflict damage to the heart to an extent similar to that induced by ischemia in terms of tissue accumulation of long-chain acylcarnitines (8) . Last, 5 pM palmitoyl-L carnitine produces not only mechanical dysfunction and energy deficiency but also membrane damage (8) , and it induces electrophysiological alterations (1, 3) in the heart. We observed that palmitoyl-L-carnitine produced mechanical dysfunction (as evidenced by an increase in LVEDP and a decrease in LVDP) and metabolic damage (as evidenced by a decrease in the tissue ATP level and an increase in the tissue AMP level). These alterations induced by palmitoyl-L-carnitine were attenuated by dilazep (1 pM), suggesting that dilazep has a beneficial effect on the palmitoyl-L-carnitine-induced mechanical dysfunction and metabolic derangements.
Dilazep has coronary vasodilating and negative iso tropic actions through inhibition of the Ca 21 channel (17, 18) . We have previously shown that dilazep decreases cardiac mechanical function (LVSP) at concentrations of 2 uM or higher (19) . In the present study, however, we used concentrations of dilazep (0.1 and 1 pM) that did not modify the mechanical function of the normal heart. In addition, dilazep would not change coronary flow, be cause the hearts were perfused at a constant flow rate. It is unlikely, therefore, that the protective effect of dilazep against the palmitoyl-L-carnitine-induced myocardial de rangements is due to an increase in coronary flow and/or a decrease in energy consumption of the heart. In fact, dilazep did not have any effect on the tissue levels of high-energy phosphates in the normal heart. These results suggest that preservation of energy is not a cause of the beneficial effect of dilazep on the palmitoyl-L-carnitine induced myocardial derangements but a result.
Dilazep has a potent inhibitory effect on the Na+ chan nel in the cardiac cells (13, 14) . According to Hashizume et al. (14) , dilazep inhibits veratridine (a Na+ channel opener)-induced hypercontracture in the rat myocytes at concentrations of 1 pM or higher (IC50=2.2,uM). On the other hand, electrophysiological studies using whole cell voltage-clamp technique have demonstrated that palmitoyl-L-carnitine activates the slow-inactivating Na+ current to increase Na+ influx and hence intracellular Na+ concentration (1, 3) . The increase in intracellular Na+ concentration may accelerate the Na+-Ca 2+ ex change system, causing intracellular Ca2+ overload, which is responsible for myocardial derangements (20) . In fact, palmitoyl-L-carnitine induces intracellular Ca2+ accumulation in the cardiac myocyte (21) . There is a possibility, therefore, that the beneficial effect of dilazep (1 pM) on the palmitoyl-L-carnitine-induced myocardial derangements is due to inhibition of Na+ influx in the cardiac cell. To examine this possibility, we studied whether tetrodotoxin, a specific inhibitor of the Na+ channel, attenuates the palmitoyl-L-carnitine-induced derangements. According to binding studies (22, 23) , the concentrations of tetrodotoxin (1 and 3 pM) used in the present study are capable of inhibiting the Na+ channel in the rat heart (Kd value=0.3 to 1 pM). The results indi cated that tetrodotoxin (1 and 3 pM) attenuated the palmitoyl-L-carnitine-induced mechanical dysfunction and metabolic derangements. Because tetrodotoxin, as well as dilazep, did not modify the energy metabolism in the normal heart, the beneficial action of dilazep against the palmitoyl-L-carnitine-induced derangements is not due to energy-sparing action but due to other actions including inhibition of the Na+ channel. The low con centration of dilazep (0.1 pM) failed to attenuate the palmitoyl-L -carnitine-induced derangements, probably because of less potent inhibitory action on the Na+ chan nel (13) .
Lysophosphatidylcholine, an amphiphilic metabolite structurally similar to palmitoyl-L-carnitine, also accumu lates in the ischemic myocardium (1, 2) . The cardiac ac tion of lysophosphatidylcholine is similar to or identical with that of palmitoyl-L-carnitine; it produces intracellu lar Ca 2+ accumulation through long-lasting bursts of Na+ channel openings (24) . Recently, Hoque et al. (25) have demonstrated that dilazep attenuates the mechanical dysfunction and metabolic derangements induced by lysophosphatidylcholine in the isolated working rat heart. Kang and Leaf (26) have shown that tetrodotoxin attenu ates the lysophosphatidylcholine-induced arrhythmias in rat myocytes. These findings support our results in terms of the cardioprotective effect of Na+ channel inhibitors.
Hoque et al. (27) reported that dilazep (1 pM) attenu ates myocardial derangements induced by ischemia and reperfusion in the isolated, working rat heart. The anti ischemic action of dilazep has been considered to be due to potentiation of the cardiovascular effects of adenosine (11, 12) . According to Meghji et al. (28) , however, con centrations of dilazep required to inhibit adenosine up take into the cardiac cell are very high (over 100 pM) in the rat when compared to other species. Nevertheless, dilazep is capable of attenuating myocardial changes in duced by palmitoyl-L-carnitine at a concentration of 1 pM. Therefore, we speculate that the action of dilazep to reduce the palmitoyl-L-carnitine-induced derangements contributes to its protective effect on the myocardium against ischemia-reperfusion damage.
In conclusion, dilazep attenuates both mechanical dys function and metabolic derangements of the heart in duced by palmitoyl-L-carnitine, and the beneficial action of dilazep is not due to preservation of energy but prob ably due to inhibition of Na+ channels of the cardiac membranes.
